Prespecified secondary analysis of FINEARTS-HF (5,006 of 6,001 with 12-month KCCQ data) in HFmrEF/HFpEF: finerenone vs placebo numerically improved all but one of 23 KCCQ components, most for leg oedema (+2.5) and fatigue (+2.2); exploratory.
Secondary analysisn = 5,006
Hamatani et al. Finerenone and quality of life in heart failure: component-level analyses and clinical relevance of the Kansas City cardiomyopathy questionnaire